McClure, J., Jack, L., Deprey, M., Catz, S., McAfee, T., Zbikowski, S., … Swan, G. (2008). Canary in a coal mine? Interest in bupropion SR use among smokers in the COMPASS trial. Nicotine and Tobacco Research, 10(12), 1815-1816.
Current best-practice treatment dictates that all smokers receive a combination of pharmacotherapy and supportive behavior therapy (Fiore, M.C., Baileey, W.C., Cohen, S.J., Dorfman, S.F., et al. , 2000; World Health Organization [WHO], 2003). Until mid-2006, only two medication were approved by the U.S. Food and Drug Administration (FDA) for this purpose in the United States – nicotine replacement therapy (NRT) and bupropion SR (Zyban). In 2006, varenicline (Chantix or Champion, depending on the market) received approval from the FDA and the European Commission.